Please login to the form below

Novavax

This page shows the latest Novavax news and features for those working in and with pharma, biotech and healthcare.

Moderna expects to supply 125 million COVID-19 vaccine doses in Q1 2021

So far, the UK has secured access to COVID-19 vaccine candidates from AstraZeneca, BioNTech/Pfizer, Novavax, Valneva, GlaxoSmithKline/Sanofi Pasteur and Janssen, as well as Moderna.

Latest news

Novavax moves closer toward launch of US phase 3 COVID-19 vaccine trial

At the same time, Novavax announced that its UK-based phase 3 trial investigating NVX-CoV2373 has competed enrolment of 15, 000 participants. ... In addition, Novavax said that over 25% of participants in this trial are over the age of 65, with a
Moderna and UK sign agreement for additional doses of COVID-19 vaccine

So far, the UK has secured access to potential COVID-19 vaccine candidates from AstraZeneca, BioNTech/Pfizer, Novavax, Valneva, GlaxoSmithKline/Sanofi Pasteur and Janssen, as well as Moderna.
EU buys 160 million doses of Moderna’s COVID-19 vaccine

The EC is also in discussions with Novavax for a potential supply deal for its COVID-19 vaccine candidate NVX-CoV2373, which is expected to begin late-stage testing by the
AZ’s COVID-19 vaccine proves promising in elderly participants, new data shows

The UK has also secured doses of Pfizer/BioNTech’s COVID-19 vaccine, as well as potential vaccines from Valneva, Sanofi/GlaxoSmithKline, Moderna, Novavax and Johnson &Johnson.
UK Vaccine Taskforce chief says first COVID-19 vaccines ‘likely to be imperfect’

The vaccine taskforce has so far secured access to six potential COVID-19 vaccines, including candidates from AstraZeneca and Oxford University, Pfizer and BioNTech, Janssen, Novavax, GlaxoSmithKline and Sanofi and Valneva.

More from news
Approximately 8 fully matching, plus 29 partially matching documents found.

Latest Intelligence

Developing a COVID-19 vaccine

The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a
Deal Watch table for June 2013

30. Isconova / Novavax. Acquisition. Proprietary vaccine adjuvant technology. 30. Unless noted, transactions are for global rights.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Dutch biotech Mucosis promotes Thomas Johnston to CEO

Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Director – Creative Healthcare Communications: Competative

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Senior Account Manager: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Account Director: Competitive

Medical Editor: Competitive

Healthcare Lead Copywriter: Competitive

PMHub

Add my company

ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...